GSK vs. BRK-B
GSK (GlaxoSmithKline plc) and BRK-B (Berkshire Hathaway Inc.) are both stocks. GSK operates in Drug Manufacturers - General (Healthcare), while BRK-B operates in Insurance - Diversified (Financial Services). Over the past 10 years, GSK returned 4.64%/yr vs 13.14%/yr for BRK-B. At a 0.26 correlation, their price movements are largely independent.
Performance
GSK vs. BRK-B - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GSK achieves a 4.91% return, which is significantly higher than BRK-B's -3.11% return. Over the past 10 years, GSK has underperformed BRK-B with an annualized return of 4.64%, while BRK-B has yielded a comparatively higher 13.14% annualized return.
GSK
- 1D
- -1.71%
- 1M
- 1.25%
- YTD
- 4.91%
- 6M
- 6.15%
- 1Y
- 27.36%
- 3Y*
- 17.87%
- 5Y*
- 4.68%
- 10Y*
- 4.64%
BRK-B
- 1D
- -0.23%
- 1M
- 2.32%
- YTD
- -3.11%
- 6M
- -2.06%
- 1Y
- -1.32%
- 3Y*
- 13.25%
- 5Y*
- 11.03%
- 10Y*
- 13.14%
GSK vs. BRK-B - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.91% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
BRK-B Berkshire Hathaway Inc. | -3.11% | 10.89% | 27.09% | 15.46% | 3.31% | 28.95% | 2.37% | 10.93% | 3.01% | 21.62% |
Correlation
The correlation between GSK and BRK-B is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.28 |
Correlation (All Time) Calculated using the full available price history since May 10, 1996 | 0.26 |
Fundamentals
GSK:
$103.15B
BRK-B:
$1.05T
GSK:
$2.85
BRK-B:
$33.62
GSK:
17.78
BRK-B:
14.49
GSK:
1.19
BRK-B:
0.56
GSK:
3.16
BRK-B:
2.80
GSK:
4.38
BRK-B:
1.44
GSK:
$32.78B
BRK-B:
$375.39B
GSK:
$23.87B
BRK-B:
$94.36B
GSK:
$11.30B
BRK-B:
$71.92B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK vs. BRK-B — Risk / Return Rank
GSK
BRK-B
GSK vs. BRK-B - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Berkshire Hathaway Inc. (BRK-B). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GSK | BRK-B | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.11 | ||
| Sortino ratioReturn per unit of downside risk | +1.60 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.00 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.48 | -0.14 | +1.62 |
| Martin ratioReturn relative to average drawdown | 3.38 | -0.30 | +3.68 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GSK | BRK-B | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.02 | -0.09 | +1.11 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.19 | 0.65 | -0.46 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.20 | 0.68 | -0.47 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.32 | 0.48 | -0.16 |
Drawdowns
GSK vs. BRK-B - Drawdown Comparison
The maximum GSK drawdown since its inception was -55.70%, roughly equal to the maximum BRK-B drawdown of -53.86%. Use the drawdown chart below to compare losses from any high point for GSK and BRK-B.
Loading charts...
Drawdown Indicators
| GSK | BRK-B | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -55.70% | -53.86% | -1.84% |
Max Drawdown (1Y)Largest decline over 1 year | -18.63% | -9.42% | -9.21% |
Max Drawdown (3Y)Largest decline over 3 years | -28.46% | -14.95% | -13.51% |
Max Drawdown (5Y)Largest decline over 5 years | -50.10% | -26.58% | -23.52% |
Max Drawdown (10Y)Largest decline over 10 years | -50.10% | -29.57% | -20.53% |
Current DrawdownCurrent decline from peak | -15.91% | -9.78% | -6.13% |
Average DrawdownAverage peak-to-trough decline | -18.87% | -11.07% | -7.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.11% | 4.49% | +3.62% |
Volatility
GSK vs. BRK-B - Volatility Comparison
GlaxoSmithKline plc (GSK) has a higher volatility of 6.42% compared to Berkshire Hathaway Inc. (BRK-B) at 3.98%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than BRK-B based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK | BRK-B | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.42% | 3.98% | +2.44% |
Volatility (6M)Calculated over the trailing 6-month period | 18.51% | 10.87% | +7.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.94% | 14.38% | +12.56% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.06% | 17.13% | +7.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.89% | 19.44% | +3.45% |
Dividends
GSK vs. BRK-B - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 3.41%, while BRK-B has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRK-B Berkshire Hathaway Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GSK GlaxoSmithKline plc | 3.41% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
Financials
GSK vs. BRK-B - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Berkshire Hathaway Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK vs. BRK-B - Profitability Comparison
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
BRK-B - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Berkshire Hathaway Inc. reported a gross profit of 26.98B and revenue of 93.68B. Therefore, the gross margin over that period was 28.8%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
BRK-B - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Berkshire Hathaway Inc. reported an operating income of 15.05B and revenue of 93.68B, resulting in an operating margin of 16.1%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
BRK-B - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Berkshire Hathaway Inc. reported a net income of 10.18B and revenue of 93.68B, resulting in a net margin of 10.9%.
Frequently Asked Questions
GSK and BRK-B have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (6.42%) compared to BRK-B (3.98%). In terms of maximum drawdown, GSK dropped -55.70% vs BRK-B's -53.86%.
GSK currently has the higher Sharpe Ratio (1.02 vs -0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GSK and BRK-B
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer